Results

• All
• Video
• Audio
• Images

• Most recent
• Filter by category

1–6 of 6 results for Carl D. Regillo

• 

  Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes

  Carl D. Regillo, MD

  Annual Meeting Talks

  2022

• 

  Number of Injections and Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER

  Carl D. Regillo, MD

  Annual Meeting Talks

  2020

• 

  Time to Dry Analysis of Brolucizumab Versus Aflibercept in Patients With Neovascular AMD: 96-Week Data From HAWK and HARRIER Trials

  Carl D. Regillo, MD

  Annual Meeting Talks

  2019

• 

  Surgical Case Conference

  Carl C. Awh, MD, FASRS

  Carl D. Regillo, MD

  Mohamed AlBahiti, MBBS, FRCSC

  Mohsin H. Ali, MD

  Nishikant J Borse, MS, FMRF, FASRS

  Jonathan S Chang, MD

  Albert Li, MD, FASRS

  Zofia Anna Nawrocka (vel Michalewska), MD, PhD

  Manish Nagpal, MD, FRCS (UK) ,FASRS

  Berna Ozkan, MD

  Uriel Rubin, MD

  Jayanth Sridhar, MD

  Victor M Villegas, MD

  Christina Y Weng, MD, MBA, FASRS

  Annual Meeting Talks

  2018

• 

  Learnings From the Lampalizumab Chroma and Spectri Phase 3 Trials: Effect of Baseline Characteristics on Geographic Atrophy Progression

  Carl D. Regillo, MD

  Annual Meeting Talks

  2018

• 

  From Sea to Shining Sea -- VBS Keynote Speaker

  Carl D. Regillo, MD

  Updates from the Field

  2019